Mont-Saint-Guibert, Belgium, November 14, 2025, 7:00 pm CET – regulated information – Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that 14,903,846 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of November 14, 2025. As a result, the Company’s total number of voting rights is now 72,383,166.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions
Figures – Modified on November 14, 2025, following the Double Voting Rights:
| Total amount of share capital (EUR) | 9,216,154.53 |
| Total Number of shares with single voting rights | 17,140,644 |
| Total Number of shares with double voting rights | 27,621,261 |
| Total Number of Shares | 44,761,905 |
| Total of voting rights | 72,383,166 |
| Total number of attributed warrants | 3,856,134 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 3,856,134 |
| Total number of diluted shares (Outstanding shares + Warrants) | 48,618,039 |
| Total number of diluted shares with voting rights | 76,239,300 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@celyad.com
Further questions about the content of this release can be sent to investors@celyad.com
